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It is generally accepted that tumour cells gain a selective
advantage by deregulation of the cell cycle as a consequence
of oncogene activation and tumour-suppressor gene inactiva-
tion (Weinberg, 1989; Hunter, 1991). There is also growing
support for the idea that tumour cells may have defective
mechanisms of programmed cell death (Wyllie, 1993). In
addition, it has been suggested that the limited lifespan of
normal human cells (Hayflick, 1965) may act as a mechanism
of tumour suppression (Sager, 1989) and that breakdown of
this limited lifespan to yield immortal variants could be a
rate-limiting step in carcinogenesis (Newbold et al., 1982;
Newbold and Overell, 1983).
Until recently support for these ideas was hampered by the
lack of molecular mechanisms of limited lifespan that were
distinct from those of cell cycle regulation. In the last 5 years
evidence has now accumulated to show that at every round
of cell division human chromosomes lose a certain amount of
DNA at the telomere that that this may be the basis of the
limited replicative lifespan of normal cells (Harley et al.,
1990). Furthermore, in order to escape this limit, 85% of
human cancers reactivate the enzyme telomerase to halt
telomeric attrition and become immortal (Counter et al.,
1994a; Kim et al., 1994). Also it is possible that many
tumour cells are dependent on telomerase for their continued
replication and survival (Feng et al., 1995) and this, coupled
with its tumour specificity, makes telomerase an attractive
target for cancer therapy (Harley et al., 1990).
The role of telomeric attrition in replicative senescence has
been the subject of several excellent commentaries recently
(de Lange 1994; Kipling, 1995; Wynford-Thomas et al., 1995)
and will be discussed only briefly here. The main purpose of
this article is to review the current knowledge on telomeric
attrition and telomerase activation in human cancer and
assess the potential value of anti-telomerases in cancer treat-
ment.
The telomere theory of limited proliferative lifespan
Telomeres are structures consisting of repeat sequences of
DNA and telomere-associated proteins that cap human
chromosomes (see Zakian, 1989; Greider, 1990; Blackburn,
1991 for recent reviews). At the telomere the DNA replica-
tion machinery leaves a gap at the 5' end of the lagging
strand, which, if it is not filled, results in the progressive
shortening of the chromosomes, a phenomenon known as the
end replication problem (Watson, 1972). Following the clon-
ing of human telomeres, two groups showed that the
telomeres of fibroblasts in vitro and tissues in vivo shortened
with both replicative lifespan in vitro (Harley et al., 1990) and
donor age in vivo (Harley et al., 1990; Hastie et al., 1990). It
has since been shown that many human cells and tissues
display the phenomenon of telomeric attrition, including
haemopoietic stem cells (Vaziri et al., 1994) and there is a
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correlation between the starting telomere length and the rep-
licative capacity of normal cultured human fibroblasts (All-
sopp et al., 1992). Also, the cells from patients who suffer
from the premature ageing syndromes, Hutchinson's progeria
and Werner's syndrome, show evidence of premature
telomeric attrition (Allsopp et al., 1992; Kruk et al., 1995).
These results have given rise to the suggestion that
telomeric attrition in the somatic cell chromosomes could act
as a cell division counter or clock (for recent critical reviews
see de Lange, 1994; Kipling, 1995; Wynford-Thomas et al.,
1995). Although the telomere clock might be short circuited
to give growth arrest in the absence of telomeric attrition, for
example by the microenvironmental signals which control
terminal differentiation, the result of telomere removal would
be the deprotection of the chromosome ends and increased
dicentric chromosome formation. This in turn may result in
replicative senescence (Benn, 1976) and if allowed to proceed
further, cell death (Counter et al., 1992). Interestingly, most
immortal tumour cells and many human tumours in vivo
possess critically short telomeres, which would normally be
expected to lead to growth arrest (see de Lange, 1994; Kipl-
ing, 1995; Wynford-Thomas, 1995 and references therein)
and so how do tumour cells solve the problem of telomere
attrition?
Telomerase in the germ line and its reactivation in human
cancer
Clearly, telomeric attrition should not be a property of the
human germ line, since if it were, the human species would
have become extinct. In fact the sperm telomeres of multicel-
lular organisms, including humans, do not suffer attrition
(Allsopp et al., 1992; Mantell and Greider, 1994) because of
the activity of the enzyme, telomerase, originally discovered
in the ciliate Tetrahymena (Greider and Blackburn, 1985).
This enzyme solves the end replication problem by filling in
the 5' gap in a highly controlled way so that normally
telomere length is sustained at each cell division, not
significantly lengthened or shortened. Telomerase is a
ribonucleoprotein; it is composed of an RNA primer encoded
by a single gene (Feng et al., 1995) and at least two protein
components of 80 and 95 kDa which have recently been
identified and cloned in Tetrahymena (Collins et al., 1995).
The regulation of telomerase activity is highly complex and
in yeast many genes have been identified that affect telomere
length (see Schulz and Zakian, 1994 and references therein).
Telomerase is reactivated when human cells are experi-
mentally immortalised in vitro (Counter et al., 1992, 1994b)
and in immortal human tumour cells (Morin, 1989; Counter
et al., 1994a; Kim et al., 1994; Nilsson et al., 1994; Hiyama et
al., 1995). More importantly, the enzyme activity is detec-
table in over 80% of human tumour samples in vivo, includ-
ing most of the common and therapeutically intractable types
(Counter et al., 1994a; Nilsson et al., 1994; Kim et al., 1994;
Hiyama et al., 1995). Furthermore, in neuroblastoma, the
level of the enzyme correlated strongly with genetic instability
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absent in three samples of stage IVS neuroblastoma that
spontaneously regressed.
Despite the strong correlation between telomerase reactiva-
tion, cellular immortalisation and cancer, the critical experi-
ment was the recent demonstration that inhibition of human
telomerase limits the lifespan of immortal human tumour
cells with critically short telomeres (Feng et al., 1995).
Therefore, telomerase reactivation appears to be causal in the
process of human cellular immortalisation and cancer pro-
gression, not merely consequential (Kipling, 1995). In addi-
tion, since telomerase is not significantly regulated through-
out the cell cycle (Mantell and Greider, 1994) these results
support the notion that normally limited lifespan presents an
independent barrier to tumour progression (Newbold et al.,
1982; Newbold and Overell, 1983; Sager, 1989) which is
distinct from cell cycle control (Weinberg, 1989; Hunter,
1991). One might also predict that some tumour-suppressor
genes may turn out to be suppressors of telomerase activity
(Sager, 1989) and preliminary evidence suggests that such a
gene may map to chromosome 3 (see Seachrist, 1995).
Most human immortal cancer cells and malignancies in vivo
exhibit telomeric attrition
There is accumulating evidence that suggests that the
majority of late stage (Paraskeva et al., 1988; Mancianti and
Herlyn, 1989; Edington et al., 1995) and recurrent (Edington
et al., 1995) human tumours are dominated by immortal cells
that have reactivated telomerase (Counter et al., 1994a; Kim
et al., 1994). Most immortal human cells have suffered so
much telomeric attrition that they have fewer than 4 kb of
telomere and only 20 population doublings remaining (Kim
et al., 1994) and most human tumours in vivo show a similar
level of attrition (Hastie et al., 1990; Counter et al., 1994a;
see also de Lange, 1994; Kipling, 1995; Wynford-Thomas et
al., 1995 and references therein). Therefore these tumours
may have multiplied to such an extent that they may be
dependent on telomerase for their continued proliferation, or
even survival, since extensive telomeric attrition of experi-
mentally transformed cells results in chromosome fusion and
cell death (Counter et al., 1992). If this is true then
telomerase antagonists might represent a novel anti-cancer
strategy with many advantages over current approaches.
Why might anti-telomerases exhibit anti-cancer activity
Normal somatic cells in vivo have plenty of telomere in
reserve, 6-9 kb even in elderly people (Hastie et al., 1990);
they do not divide as often as cancer cells and have undetec-
table telomerase activity (Kim et al., 1994). Therefore,
antagonism of telomerase should be specific to tumours
dominated by immortal cells with short telomeres and might
culminate in specific apoptosis of the tumour population
(Hiyama et al., 1995), which is a recently stated goal of
cancer therapists (Hickman, 1992). Normal germ cells with
long telomeres and constitutive telomerase activity (Allsopp
et al., 1992; Kim et al., 1994), and perhaps somatic stem
cells, would be even less vulnerable to the consequences of
telomerase antagonists than non-stem somatic cells. Although
it is not known what damage the germ line might sustain by
the prolonged use of such drugs, the fact that most cancer
patients are of post-reproductive age offsets this problem to
some extent. It is only tumour cells that have proliferated
extensively in the absence of telomerase activity which are
likely to develop critically short telomeres and be vulnerable
to anti-telomerases. Finally, as immortal variants with active
telomerase are selected late in human tumour progression
(Mancianti and Herlyn, 1989; Paraskeva et al., 1988; Counter
et al., 1994a; Kim et al., 1994; Edington et al., 1995),
telomerase antagonists may be useful when traditional
methods of cancer therapy, generally most effective against
early stage cancer, have failed. Thus, anti-telomerases pro-
mise a novel, and for the first time tumour-specific, approach
to cancer therapy that might also be effective against
advanced and disseminated tumours.
In arguing against the value of anti-telomerase therapy
Kipling (1995) pointed out that the phenotypic lag caused by
20 population doublings would allow a marble-sized tumour
to grow to the size of a small family car. Firstly, this is an
unrealistic estimate based on the behaviour of in vitro cell
populations and in vivo only a small proportion of most solid
tumours actually divides. Secondly, it is very likely that the
number of human tumour cell divisions is not matched by an
equivalent increase in tumour mass; even in advanced
tumours many cells continue to terminally differentiate and
many tumour cells are continually lost through apoptosis
(Wyllie, 1993) or attack from the host defences (Esteban et
al., 1990; Wolf et al., 1990). Finally, even if the argument of
phenotypic lag turns out to be true, it would still be possible
to use telomerase antagonists to prevent recurrence once
conventional therapy has reduced the tumour burden to
several thousand cells (Goldie and Coldman, 1979). It is
nevertheless true that many human tumours and some
immortal cell lines have very long telomeres regardless of the
level of telomerase activity (Kim et al., 1994; Hiyama et al.,
1995). The significance of these observations is still unclear
(Kipling, 1995) and may suggest that at least some tumours
may not respond to anti-telomerases.
Possible mechanisms of resistance to telomerase antagonists
Telomerase-negative tumours with long telomeres may have
arisen from a tissue or target cell, e.g. a germ cell (Wynford-
Thomas et al., 1995) or somatic stem cell, which originally
possessed a longer than average telomere and consequently
enough proliferative power to generate an advanced tumour
without cellular immortalisation. Alternatively these tumours
may have solved the end replication problem by a mechanism
that does not involve telomerase, and recombinational
mechanisms of dealing with telomeric attrition are known
from studies of Saccharomyces (Wang and Zakian 1990;
Lundblad and Blackburn, 1993) and Drosophila (Biessman et
al., 1990; Levis et al., 1993). Some advanced tumours are
mortal (Edington et al., 1995) and these tumours may
account for the 15% of advanced human tumours that are
telomerase negative (Kim et al., 1994), but it is also possible
that recombinational mechanisms of telomere healing are at
work in telomerase-positive cells such as HeLa (Morin, 1989)
and human keratinocytes transformed by human papil-
lomavirus (Klingelhutz et al., 1994), both of which show
evidence of telomere healing. It is difficult to see how selec-
tion for telomerase activation could take place unless at least
some of the tumour cells have at some stage possessed
critically short telomeres (Counter et al., 1992). However,
since cells with shorter telomeres may have a selective advan-
tage under certain circumstances (Larson et al., 1987), it is
still possible that some tumour cells in some telomerase-
positive tumours may have long telomeres, especially as the
telomerase TRAP assay is capable of detecting just one
positive cell in one thousand (Kim et al., 1994; Kipling,
1995). Lastly, in the case of both telomerase-positive and
-negative tumours the apparent appearance of long
telomeres, as assessed by Southern blotting, could be
misleading. The presence of large numbers of contaminating
normal cells, or cells with many dicentric chromosomes, may
lead to the spurious detection of long telomeres and even
tumour cells that have long telomeres on average may have
at least one telomere that is critically short (de Lange, 1994).
These technical problems could be resolved if reliable in situ
methods of quantitating telomere length are developed and
applied.
Clearly, one mechanism of resistance to anti-telomerases
relates to the argument that not enough tumour cells have a
critically short telomere for the drug to eliminate the turn-
over rapidly enough (Kipling, 1995) and this has been dis-
cussed above. There is a definite need to understand what a
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and how it leads to cell death during crisis (Counter et al.,
1992), as well as understanding how telomere length changes
throughout tumour progression and following cancer
therapy. In addition, even tumours with critically short
telomeres and active telomerase may become resistant to
anti-telomerases, perhaps by abrogating signalling from the
shortened telomere to the cell cycle or the apoptosis
mechanisms. Finally, it is still a possibility that telomerase
antagonists, like many other drugs, may become
therapeutically inactive as a result of resistance mechanisms
that prevent sufficient drug reaching telomerase. For ins-
tance, resistance to many anti-cancer drugs can be caused by
increased efflux of a drug from the cell (Gottesman, 1993). It
is also possible that in large tumours with poor blood supp-
lies the drugs may have difficult reaching the target cells, but
if non-toxic specific anti-telomerases can be designed this and
other conventional therapeutic problems should be lessened.
The lack of similarity of the telomerase protein com-
ponents to other known polymerases (Collins et al., 1995)
encourages the belief that anti-telomerases of high specificity
could be designed. Despite the fact that such drugs are
presently a possibility rather than a reality and the potential
problems detailed in this article, telomerase is an enzyme that
has considerable potential for cancer therapy. The challenge
now is to investigate some of the issues raised above so that
this potential may one day be realised.
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